Cryovida

Name

Cryovida

Legal name

CRYOVIDA

Website

https://cryovidastemcells.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine
• Stem cell therapy
• Cellular biotechnology
• Mesenchymal stem cells
• Immunotherapy

Headquarters

HQ city

Mexico

HQ country

Mexico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Stem Cell Therapy Treatments: Revenue from providing human mesenchymal stem cell treatments for various medical conditions including autoimmune diseases, chronic-degenerative diseases, musculoskeletal disorders, diabetes, cancer support, and aesthetic treatments.
2. Medical Certification Programs: Revenue from medical training and certification programs for healthcare professionals in regenerative medicine. Three tiers available: Pure-Shot 10 MI ($5,000 MXN), Hybrid ($7,500 MXN), and Total ($10,990 MXN).

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Cryovida develops, produces, and administers human mesenchymal stem cell therapies at a GMP/ISO-certified laboratory in Mexico, treating chronic-degenerative, autoimmune, musculoskeletal, diabetes, rheumatoid arthritis, aesthetic, and oncology-support conditions, and cryopreserves stem cells for patients. The company also generates revenue from tiered medical certification programs for healthcare professionals in regenerative medicine, plus physician referral channel management.

Product overview

Cryovida operates as a single integrated platform offering human stem cell banking and mesenchymal stem cell-based regenerative medicine therapies in Mexico. The core offering comprises stem cell cryopreservation services and seven distinct therapeutic treatment services targeting different medical conditions: Anti-Aging/Esthetic, Rheumatoid Arthritis, NK Cell Cancer Treatment, Musculoskeletal Disorders, Diabetes Mellitus, Autoimmune Diseases, and Chronic-Degenerative Diseases. All treatments are grounded in mesenchymal stem cell technology, supported by the company's GMP/ISO-certified laboratory, and personalized through medical assessment protocols. Additionally, Cryovida provides medical education and certification programs for healthcare professionals seeking to integrate regenerative medicine into their clinical practice.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem Cell Banking Cryopreservation and storage of human mesenchymal stem cells under GMP, ISO 6, and ISO 5 certified laboratory conditions, compliant with COFEPRIS regulations and NOM-059-SSA1-2015 standards, offered to patients and providers in Mexico.
• Anti-Aging / Aesthetic Regenerative Treatment Facial regenerative treatment using human mesenchymal stem cells to stimulate natural collagen and elastin production, reduce wrinkles and spots, and restore skin firmness, targeting patients seeking anti-aging rejuvenation rather than conventional aesthetic procedures.
• Rheumatoid Arthritis Regenerative Treatment Regenerative therapy using mesenchymal stem cells to modulate inflammatory response, support tissue regeneration, and improve articular function in rheumatoid arthritis patients, including early and advanced stages with persistent joint pain and morning stiffness.
• NK Cell (CNK) Cancer Treatment Complementary immunotherapy using Natural Killer (NK) cells to support the immunological response of oncology patients as part of an integrated cancer management approach alongside conventional treatments.
• Musculoskeletal Disorders Regenerative Treatment Regenerative therapy for musculoskeletal conditions including joint and tendon injuries, chronic pain, sports injuries, and degenerative joint wear using mesenchymal stem cells to support tissue regeneration and improve mobility.
• Diabetes Mellitus Regenerative Treatment Complementary regenerative treatment for Diabetes Mellitus types 1 and 2 using mesenchymal stem cells to support metabolic function, reduce inflammatory processes, and protect organs and tissues.
• Autoimmune Diseases Regenerative Treatment Regenerative therapy using mesenchymal stem cells to modulate immune system response, reduce chronic inflammation, and support tissue regeneration in autoimmune conditions including lupus, rheumatoid arthritis, multiple sclerosis, Crohn's disease, and psoriasis.
• Chronic-Degenerative Diseases Regenerative Treatment Regenerative treatment for chronic-degenerative diseases including neurodegenerative, cardiovascular, and osteoarticular degenerative conditions, using mesenchymal stem cells to support tissue regeneration, reduce inflammatory processes, and improve quality of life.
• Medical Certification in Regenerative Medicine Scientifically and academically endorsed certification program for medical professionals in regenerative medicine, focusing on clinical application of mesenchymal stem cells, offered in three paid tiers: Pure-Shot 10 MI at $5,000 MXN, Hybrid at $7,500 MXN, and Total at $10,990 MXN.

Quantifiable outcome

• Symptom improvement ranging from 30% to 90% depending on case and condition
• +1 more outcomes

Named customers5 records

Segments8 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Scripa InstituteminorStrategic or Co-development Partner · 24 July 2026Scripa Institute appears to be a partner for medical certification programs. Cryovida's 59th medical certification in regenerative medicine uses scripainstitute.com for registration and payment processing. The partnership involves academic and scientific committee-backed certifications focused on clinical application of mesenchymal stem cells.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• StemGenex: US-based stem cell treatment provider offering autologous therapies for inflammatory and degenerative conditions. Directly comparable clinic-based autologous cell therapy model serving medical tourism patients.
• Mesoblast: Australia-listed developer of MSC-based therapies for inflammatory and immunologic conditions. Closely comparable to Cryovida as a regenerative medicine company built around mesenchymal stem cell technology targeting chronic disease.
• Pluristem Therapeutics: Israeli cell therapy company developing placenta-derived MSC therapies. Comparable as a developer of allogeneic MSC products targeting similar regenerative and inflammatory indications.
• Athersys: US-based clinical-stage developer of MultiStem cell therapy for inflammatory, neurological, and cardiovascular conditions. Comparable regenerative medicine peer operating in the MSC/stromal cell therapy space.
• Ingeneron: US-based regenerative medicine company developing autologous adipose-derived stem cell therapies. Comparable in using adipose tissue as a cell source and targeting orthopedic and chronic indications.
• BrainStorm Cell Therapeutics: Cell therapy company developing autologous MSC-based therapies (NurOwn) for neurodegenerative diseases. Comparable as a developer of MSC-derived therapies targeting chronic-degenerative indications.
• Cells for Cells: Chile-based stem cell company developing MSC-based therapies for osteoarthritis and other conditions. Direct LATAM peer sharing Cryovida's MSC focus, autologous cell therapy model, and clinical positioning in Latin America.
• Novadip: Belgian MSC-based regenerative medicine company developing autologous cell therapies for bone and soft tissue reconstruction. Comparable developer of MSC-derived therapies in the regenerative space.

Broad incumbents

• Regenexx: Established US regenerative medicine network offering orthopedic stem cell treatments. Comparable as a scaled provider in the orthobiologic/regenerative medicine clinic segment, but with broader portfolio and US-based operations.

Emerging players

• Holostem Terapie Avanzate: Italian advanced therapies company developing stem cell-based treatments for rare diseases and regenerative applications. Comparable in operating a specialized cell therapy manufacturing platform with regulatory-grade facilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@cryovidamx
• Facebookfacebook.com/CryoVidaMx
• Instagraminstagram.com/cryovidamx
• LinkedInlinkedin.com/company/cryovida

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cryovida